Blog: MS news

New guidance on MS Society grants

27 January 2020

Source MS Society: Our Health and Wellbeing grants are there to help you pay for items that will have a significant positive impact on your life.

Online Fatigue- management course

27 January 2020

Source MS Society: This online course will help you find ways to manage your MS fatigue and explain it to other people.

Siponimod licensed for secondary progressive MS

24 January 2020

Source MS Society: This week the European Medicines Agency (EMA) granted a license for siponimod (brand name Mayzent) to treat adults with secondary progressive MS with active disease.

It's time to look at mountain escapes with a fresh perspective.

24 January 2020

Source Winter Sports Travel: Making Travel Accessible. Winter sports are becoming more accessible than ever before. But finding the right place or activity when you're living with a challenging condition can be tough.

Try this tool to find sports and resorts in Europe that are tailored to your needs. Click here.

Plegridy approved for relapsing remitting MS in England

24 January 2020

Source MS Trust: NICE has published its final decision recommending that Plegridy can be prescribed by the NHS for relapsing-remitting MS.

MS Progression Affected by Degree of Relapse Recovery and Timing of DMT Use, Study Says

21 January 2020

Source Multiple Sclerosis News Today: Recovering well after a first relapse and starting a disease-modifying therapy (DMT) immediately afterwards considerably increases the likelihood of slowing progression in multiple sclerosis (MS), a study suggests.

Its findings support relapse recovery as a critical factor for DMT initiation, and one that should be assessed routinely in MS clinical trials, researchers said.

The study, “Relapse recovery: The forgotten variable in multiple...

New Study Asks: When Does MS Begin?

21 January 2020

Source National Multiple Sclerosis Society: Researchers from the Harvard T.H. Chan School of Public Health in Boston and collaborators report on a study that examined blood (serum) samples from 60 military personnel who went on to develop multiple sclerosis years later. Compared to samples from a control group, those who eventually developed MS showed higher than usual levels of a molecule (neurofilament light chain - NfL) that reflects damage to the nervous system.

The levels of NfL...

Cannabis-based medicines: Two drugs approved for NHS

11 November 2019

Source BBC: Two cannabis-based medicines, used to treat epilepsy and multiple sclerosis, have been approved for use by the NHS in England.

European drug regulator recommends restricted use of Lemtrada

11 November 2019

Source MS Trust: Lemtrada (alemtuzumab) should be restricted to people with highly active relapsing-remitting MS according to a review carried out by the European Medicines Agency's (EMA) drug safety committee.

Sativex cost-effective in final NICE guideline on cannabis-based medicines

11 November 2019

Source MS Trust: Sativex is a cost-effective treatment for people with MS spasticity according to new guidance published today by NICE(link is external). This reverses the decision made in draft guidance published earlier this year.

Pages

Category

Archive